The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback